助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   免疫诱导治疗 的翻译结果: 查询用时:0.271秒
图标索引 在分类学科中查询
所有学科
更多类别查询

图标索引 历史查询
 

免疫诱导治疗
相关语句
  immunity induction
     Immunity induction therapy was performed with Zenapax one hour before preoperation,Immunosuppressive drugs consisted of FK506,MMC and corticosteroid.
     术前1小时予赛尼哌(Zenapax)行免疫诱导治疗。 术后免疫抑制治疗采用普乐可复(FK506)、骁悉(MMC)、激素联合应用。
短句来源
     CONCLUSION: Zenapax used for immunity induction of renal transplantation can prevent and reduce the occurrence of acute reject reaction,it has safety and good tolerance.
     结论:赛尼哌用于肾移植的免疫诱导治疗,可以预防和减少急性排斥反应的发生,安全性和耐受性好。
短句来源
  “免疫诱导治疗”译为未确定词的双语例句
     Anti-CD25 Ab (Zenapax) induction therapy in sensitized recipients of renal transplantation
     抗CD25抗体在致敏受者肾脏移植免疫诱导治疗中的临床观察
短句来源
     The dosages of ALG (induced immune-inhibited therapy) in the recipients with CMV infection or no CMV infection were ( 14.1± 1.32) and ( 13.2± 0.92) respectively with the difference being not significant (P> 0.05).
     CMV感染和无CMV感染的肾移植受者ALG免疫诱导治疗疗程分别为 ( 4 .7± 1.3 2 )d、( 4 .4± 0 .92 )d ,使用剂量分别为 ( 14 .1± 1.3 2 )支、( 13 .2±0 .92 )支 ,差异无显著性 (P >0 .0 5 )。
短句来源
     Methods 214 recipients were treated with methylprednisolone (MP), antilymphocyte globulin (ALG) as induced immune-inhibited therapy after renal transplantation.
     方法 2 14例肾移植受者术后给予甲泼尼龙 (MP)、抗淋巴细胞球蛋白 (ALG)静脉滴注作为免疫诱导治疗
短句来源
     Immunodepressive therapy with low doses of ALG may not increase the incidence of CMV infection.
     术后短期的ALG免疫诱导治疗可能不增加CMV感染发生率 ;
短句来源
     The humanized mAb Daclizumab(Zenapax) was given to recipient as immuned induction treatment at preoperative one hour and postoperative 14 days respectively. Baseline immunosuppressive drugs consisted of FK506,mycophenolate mofetil(MMF) and corticosteroid.
     术前 1h及术后 14d给予Daclizumab行免疫诱导治疗 ,术后免疫抑制治疗包括FK5 0 6、霉酚酸酯 (MMF)及激素。
短句来源
更多       
  相似匹配句对
     Induced Immune Tolerance for Therapy of EAU
     诱导免疫耐受治疗实验性自身免疫性葡萄膜炎
短句来源
     Primary Exploration on Rheumatoid Arthritis Treatment by Traditional Chinese Medicine Induced Tolerance
     中医药诱导免疫耐受治疗类风湿关节炎初探
     Tumor antigens recognized by immune system
     诱导免疫应答的肿瘤抗原
短句来源
     constraint-induced movement therapy,CI
     强制性诱导运动治疗
     (3) Immunogene therapy;
     (3)免疫基因治疗;
短句来源
查询“免疫诱导治疗”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  immunity induction
For one thing the antigen caused immunity induction and for another the tolerance formation represent acentral phaenomenon which includes in any case the entire organism.
      


Objectives To investigate the incidence of cytomegalovirus (CMV) infection and the effects of immunodepressive on CMV infection in renal allograft recipients.Methods 214 recipients were treated with methylprednisolone (MP), antilymphocyte globulin (ALG) as induced immune-inhibited therapy after renal transplantation. The baseline immune-inhibited therapy was cyclosporine A, prednisone plus immurane. Methylprednisolone was prescribed to treat acute reject reactions(AR). If MP showed no effect, ALG or OKT3...

Objectives To investigate the incidence of cytomegalovirus (CMV) infection and the effects of immunodepressive on CMV infection in renal allograft recipients.Methods 214 recipients were treated with methylprednisolone (MP), antilymphocyte globulin (ALG) as induced immune-inhibited therapy after renal transplantation. The baseline immune-inhibited therapy was cyclosporine A, prednisone plus immurane. Methylprednisolone was prescribed to treat acute reject reactions(AR). If MP showed no effect, ALG or OKT3 was prescribed. CMV-PP65 antigen was detected by using immunocytochemical methods at weekly intervals during the first 3 months after transplantation.Results 126 out of 214 recipients ( 61.7%) developed CMV infection. The antigen-positive cells were detected at the day ( 25.4± 14.7) with the average antigen-positive cells being ( 9.2± 7.9) per 50 000 leukocytes. The incidence of AR in the renal transplant recipients before CMV infection was 42.3% (52/126),and was obviously higher than in those without CMV infection ( 20.5%, P< 0.01). Among the 52 recipients with AR reaction, 23 and 16 of them were treated with ALG or OKT3 respectively, significantly more than that of the recipients with no CMV infection to treat acute reject reaction with ALG or OKT3 (P< 0.05). The dosages of ALG (induced immune-inhibited therapy) in the recipients with CMV infection or no CMV infection were ( 14.1± 1.32) and ( 13.2± 0.92) respectively with the difference being not significant (P> 0.05).Conclusions The incidence of CMV infection in renal allograft recipients is high. Immunodepressive therapy with low doses of ALG may not increase the incidence of CMV infection. The therapy with ALG or OKT3 after acute reject reaction may be relative with CMV infection in renal allograft recipients.

目的 探讨肾移植受者巨细胞病毒 (CMV)感染率及免疫抑制剂对其的影响。方法 2 14例肾移植受者术后给予甲泼尼龙 (MP)、抗淋巴细胞球蛋白 (ALG)静脉滴注作为免疫诱导治疗。基础免疫抑制剂治疗为环孢素A +泼尼松 +硫唑嘌呤。急性排斥反应时给予MP冲击治疗 ,无效时给予ALG或OKT3治疗。采用免疫细胞化学LSAB法测定外周血白细胞CMV PP65抗原。结果 CMV感染率为 61.7% ( 12 6/ 2 14 ) ,初次检出CMV PP65抗原的时间为术后 ( 2 5 .4± 14 .7)d ,平均抗原阳性细胞数为每 5 0 0 0 0白细胞 ( 9.2± 7.9)个。CMV感染的肾移植受者在感染前急性排斥反应率为4 2 .3 % ( 5 2 / 12 6) ,明显高于无CMV感染受者的 2 0 .5 % (P <0 .0 1) ;使用ALG或OKT3治疗例数分别为 2 3、15例 ,也高于无CMV感染的受者 (P <0 .0 5 )。CMV感染和无CMV感染的肾移植受者ALG免疫诱导治疗疗程分别为 ( 4 .7± 1.3 2 )d、( 4 .4± 0 .92 )d ,使用剂量...

目的 探讨肾移植受者巨细胞病毒 (CMV)感染率及免疫抑制剂对其的影响。方法 2 14例肾移植受者术后给予甲泼尼龙 (MP)、抗淋巴细胞球蛋白 (ALG)静脉滴注作为免疫诱导治疗。基础免疫抑制剂治疗为环孢素A +泼尼松 +硫唑嘌呤。急性排斥反应时给予MP冲击治疗 ,无效时给予ALG或OKT3治疗。采用免疫细胞化学LSAB法测定外周血白细胞CMV PP65抗原。结果 CMV感染率为 61.7% ( 12 6/ 2 14 ) ,初次检出CMV PP65抗原的时间为术后 ( 2 5 .4± 14 .7)d ,平均抗原阳性细胞数为每 5 0 0 0 0白细胞 ( 9.2± 7.9)个。CMV感染的肾移植受者在感染前急性排斥反应率为4 2 .3 % ( 5 2 / 12 6) ,明显高于无CMV感染受者的 2 0 .5 % (P <0 .0 1) ;使用ALG或OKT3治疗例数分别为 2 3、15例 ,也高于无CMV感染的受者 (P <0 .0 5 )。CMV感染和无CMV感染的肾移植受者ALG免疫诱导治疗疗程分别为 ( 4 .7± 1.3 2 )d、( 4 .4± 0 .92 )d ,使用剂量分别为 ( 14 .1± 1.3 2 )支、( 13 .2±0 .92 )支 ,差异无显著性 (P >0 .0 5 )。结论 肾移植术后CMV感染率高 ;术后短期的ALG免疫诱导治疗可能不增加CMV感染发生率 ;急性排斥反应发生后免疫抑制剂尤其是ALG或OKT3的使用与术后CMV感染密切相关。

Purpose To investigate the surgical techniques,clinical experiences and therapeutic effects of combined liver kidney transplantation(CLKT) Methods Combined liver kidney transplantation was performed on one patient with liver cirrhosis and hepatic encephalopathy of hepatitis B and uremia of chronic nephritis complicated with milticapsular liver,bilateral kidney and portal vein stenosis. ABO blood type incompatible but matched (group O to B)cadave ric allografts were used in the CLKT. Liver and kidney...

Purpose To investigate the surgical techniques,clinical experiences and therapeutic effects of combined liver kidney transplantation(CLKT) Methods Combined liver kidney transplantation was performed on one patient with liver cirrhosis and hepatic encephalopathy of hepatitis B and uremia of chronic nephritis complicated with milticapsular liver,bilateral kidney and portal vein stenosis. ABO blood type incompatible but matched (group O to B)cadave ric allografts were used in the CLKT. Liver and kidney transplantation was carried out by using orthotopic and ordinary methods respectively.The humanized mAb Daclizumab(Zenapax) was given to recipient as immuned induction treatment at preoperative one hour and postoperative 14 days respectively.Baseline immunosuppressive drugs consisted of FK506,mycophenolate mofetil(MMF) and corticosteroid.Lamividine was used on day 60 preoperation and day 7 postoperation respectively.In the meantime hepatitis B immunoglobin (HBIg) was injected musclely. Results The complications included acute and chronic rejection has not been taken placed since the transplantation day.Both transplant organs had rapidly normal functions postoperation,without primary nonfunction of liver graft happened.The patients has been survived for 10 months with normal life quality. Conclusions Skilled operation techniques,comprehensive monitoring perioperatively and correct management are all major factors for success.ABO blood type incompatible but matched(group O to B) cadaveric CLKT can be performed safely.The induction treatment of Zenapax and baseline immunosuppression consisted of FK506,MMF and corticosteroid are effective and safe.Combination therapies of Lamividine and HBIg to prevent HBV recurrence may be more effective.

目的 总结并探讨肝肾联合移植的手术技术、临床治疗经验及疗效。方法 患者因多囊肝并门脉主干先天性狭窄畸形、双侧多囊肾及乙型肝炎后肝硬化、反复发作性肝性脑病 ,并伴有慢性肾功能衰竭而施行一期肝肾联合移植。供、受体血型不一致但相匹配 (O型 -B型 )。肝移植采用经典的原位肝移植技术 ,肾移植采用常规方法。术前 1h及术后 14d给予Daclizumab行免疫诱导治疗 ,术后免疫抑制治疗包括FK5 0 6、霉酚酸酯 (MMF)及激素。分别于术前 60d和术后 7d开始服用抗乙肝病毒药 (贺普丁、Laminvudine) ,并肌注乙肝免疫球蛋白 (HBIg)。结果 受者术后无手术并发症发生 ,移植肝、肾功能恢复良好 ,乙型肝炎再感染被控制 ,现已术后近 10个月。结论 完善的手术技巧、围手术期的严密监测及并发症的及时正确处理等是肝肾联合移植成功的重要条件 ;ABO血型不一致但符合输血原则的供受体间进行肝或肝肾联合移植可以取得良好的临床治疗效果 ;Daclizumab的免疫诱导加以FK5 0 6为主的三联治疗免疫抑制效果良好 ;联合应用Laminvudine和HBIg预防乙肝复发效果更好

Objective To explore the efficacy and safety of anti-CD25 Ab (Zenapax) induction therapy in sensitized recipients following renal transplantation. Methods Thirty-six sensitized recipients were retrospectively analyzed and divided into Zenapax group and OKT3 group. Main immunosuppressive therapy regimen consisted of steroids, acrolimus or cyclosporine and mycophenolate mofetil in all recipients. Zenapax group received 2-dose Zenapax (50?mg) intravenous infusion on day 0 and week 2. OKT3 group received OKT3 (5?mg,...

Objective To explore the efficacy and safety of anti-CD25 Ab (Zenapax) induction therapy in sensitized recipients following renal transplantation. Methods Thirty-six sensitized recipients were retrospectively analyzed and divided into Zenapax group and OKT3 group. Main immunosuppressive therapy regimen consisted of steroids, acrolimus or cyclosporine and mycophenolate mofetil in all recipients. Zenapax group received 2-dose Zenapax (50?mg) intravenous infusion on day 0 and week 2. OKT3 group received OKT3 (5?mg, daily) intravenous infusion from postoperative day 1 to day 5 or 10. Results The demographics were not significantly different between Zenapax group and OKT3 group. During a follow-up of 6 months 4 cases were subjected to acute rejection (AR) in Zenapax group and 3 in OKT3 group ( P > 0.05 ). In Zenapax and OKT3 groups, 1 and 2 allografts were removed as a result of rupture respectively. 4 cases were suffered from delayed graft function(DGF) in Zenapax group and 9 in OKT3 group respectively with the difference being significant ( P < 0.01 ). The incidence of allergy cytokine release syndrome and infection in Zenapax group were significantly lower than in OKT3 group ( P < 0.05 ). Conclusion Zenapax is a safe and effective induction therapy in sensitized recipients and can substitute for OKT3 in renal transplantation.

目的 评价致敏受者肾脏移植应用抗CD2 5抗体 (赛尼哌 )作为免疫诱导治疗的有效性和安全性。方法 将 36例接受肾移植的致敏受者随机分为两组 ,赛尼哌组 18例 ,OKT3组 18例。所有患者免疫抑制维持治疗为他克莫司 (FK5 0 6 )或环孢素A(CsA) +霉酚酸酯 (MMF) +泼尼松(Pred)三联疗法。赛尼哌组 :分别在术前 2 4h和术后 14d静脉内输入 5 0mg赛尼哌 ;OKT3组 :术后第 1d开始应用OKT3,每天 5mg ,持续 5~ 10d。观察两组术后半年内急性排斥 (AR)、移植肾功能延迟恢复 (DGF)的发生情况。结果 有 7例患者术后发生AR ,其中赛尼哌组 4例 ,OKT3组 3例。有13例发生DGF ,其中赛尼哌组 4例 ,OKT3组 9例 (P <0 .0 1)。在过敏反应、细胞因子释放综合征、神经系统症状、感染等方面 ,赛尼哌组发生率明显低于OKT3组 (P <0 .0 5 )。结论 赛尼哌是一种强效安全的免疫抑制剂 ,在致敏受者肾移植的免疫诱导治疗中效果满意。

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关免疫诱导治疗的内容
在知识搜索中查有关免疫诱导治疗的内容
在数字搜索中查有关免疫诱导治疗的内容
在概念知识元中查有关免疫诱导治疗的内容
在学术趋势中查有关免疫诱导治疗的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社